



Welcome to the opening and first annual  
symposium of KGJ Centre for Myeloid Cancers

**c-myc**

11-12th of September 2024

Bergen Norway



UNIVERSITY  
OF BERGEN

# WEDNESDAY

Wednesday, 11 September, 2024 | 10:30

Grand Bergen

Nedre Ole Bulls plass 1, 5012 Bergen

## 10:30 REGISTRATION & COFFEE

## 11:00- 12:00 OPENING

- 11:00- 11:10 Bjørn Tore Gjertsen, C-MYC Centre Director
- 11:15- 11:20 Anne Marie Haga, KG Jebsen Foundation
- 11:25- 11:35 Olav Ljøsne, Chair Blodkreftforeningen
- 11:35- 11:40 Per Bakke, Dean. Medical Faculty, University of Bergen
- 11:45- 11:50 Clara Gjesdal, Vice CEI, Haukeland University Hospital
- 11:55- 12:00 Silke Appel, Chair, Department of Clinical Sciences, University of Bergen
- 12:00- 12:05 Kahtan Al-Azawy, Director, Department of Medicine, Haukeland University Hospital

## 12:05-13:20 LUNCH

### SCIENTIFIC PROGRAM

- 13:20- 14:00 **Targeting Epigenetics: A new strategy in myeloid cancer prevention?** - Kirsten Grönbek
- 14:00- 14:40 **Molecular measurable residual disease monitoring in Acute Myeloid Leukemia (AML)**- Konstanze Döhner
- 14:40- 15:20 **What is meant by “responsible” cancer research?**- Roger Strand
- 15:20- 15:30 Concluding remarks and introduction of symposium day 2, Bjørn Tore Gjertsen

# THURSDAY



Thursday 12 September, 2024 | 08:30  
Grand Bergen

## 08:30 REGISTRATION & COFFEE

Chair Bjørn Tore Gjertsen

09:00- 09:20 **Demultiplexing cell identity-** Simona Chera,  
Co-director KGJ c-myc

09:20- 09:40 **Towards single-cell profiling of translation  
and isoforms** - Eivind Valen, KGJ c-myc

09:40- 10:00 **Minimal residual disease in Myelodysplastic  
Syndrome** - Astrid Olsnes

10:00- 10:20 **Allogeneic hematopoietic stem cell  
transplantation for myeloid malignancies -  
from patient`s bed to multiomics?** - Håkon  
Reikvam

## 10:20-10:30 BREAK

Chair Simona Chera

10:30- 10:50 **Novel approaches to the prevention of acute  
graft versus host disease-** Yngvar Fløisand

10:50- 11:10 **AML Modelling: Past, present and future  
directions** - Emmet Mc Cormack

11:10- 11:30 **How can we make use of the p53 code in the  
clinic?** - JC Bourdon

11:30- 12:00 **Functional precision medicine for overcoming  
drug resistance in elderly/unfit AML patients**  
- Krister Wennerberg

## 12:00-13:00 LUNCH

# THURSDAY

Thursday 12 September, 2024 | 13:00

Grand Bergen

## SCIENTIFIC PROGRAM

Chair Eivind Valen

13:00- 13:20 **Generating evidence from Real World Data in hematology-** Kimmo Porkka

13:20- 13:40 **Evolutionary landscape of clonal hematopoiesis** - Gerwin Huls

13:40- 14:00 **Novel candidate targets for future AML therapies: Glycosaminoglycans and DNA-PK** - Kim Theilgaard-Monch

14:00- 14:20 **Targeting NAMPT in -7/-7q Myeloid Blood Cancers** - Caroline Heckman

## 14:20-14:40 BREAK

Chair Håkon Reikvam

14:40- 15:00 **Clinical forecasting of Acute Myeloid Leukemia by ex vivo drug sensitivity screening** - Jorrit Enserink

15:00- 15:20 **Ex Vivo Venetoclax Sensitivity Testing Predicts Treatment Response in AML** - Mika Kontro

15:20- 15:40 **A Phase 1 study to study 5-FU-mir-15a (CR001) in AML** - Andrea Lenartova

15:40- 16:00 **Quality of life studies in AML in Sweden** - Vladimir Lazarevic

16:00- 16:20 **Metabolic rewiring as targetable entity in AML** - JJ Schuringa

16:20- 16:40 **Closing remarks** - *Simona Chera, Co-director, c-myc*